VOLORIDGE INVESTMENT MANAGEMENT, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
VOLORIDGE INVESTMENT MANAGEMENT, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,044,785
-53.2%
56,353
-66.1%
0.01%
-54.5%
Q1 2023$2,233,772
-33.2%
166,327
-38.5%
0.01%
-42.1%
Q4 2022$3,345,355
-28.1%
270,441
-19.0%
0.02%
-24.0%
Q3 2022$4,656,000
+7.9%
333,729
+6.8%
0.02%
+13.6%
Q2 2022$4,315,000
-12.0%
312,476
+3.7%
0.02%
-21.4%
Q1 2022$4,901,000
+27.5%
301,213
+27.6%
0.03%
+33.3%
Q4 2021$3,844,000
-8.2%
235,996
-16.3%
0.02%
-22.2%
Q3 2021$4,189,000
-35.1%
282,062
-12.7%
0.03%
-40.0%
Q2 2021$6,455,000
-22.5%
323,236
-10.4%
0.04%
-26.2%
Q1 2021$8,325,000
-9.2%
360,685
-2.9%
0.06%
-20.8%
Q4 2020$9,172,000
-29.7%
371,324
+17.9%
0.08%
-29.4%
Q3 2020$13,053,000
+692.1%
314,839
+815.2%
0.11%
+473.7%
Q2 2020$1,648,000
-1.1%
34,402
+30.0%
0.02%
-60.4%
Q1 2020$1,667,000
-51.6%
26,472
-4.8%
0.05%
-28.4%
Q4 2019$3,445,000
+1431.1%
27,801
+720.1%
0.07%
+1575.0%
Q3 2019$225,000
-63.9%
3,390
-39.2%
0.00%
-78.9%
Q1 2019$624,000
-43.1%
5,574
-48.7%
0.02%
-62.0%
Q4 2018$1,096,000
+14.3%
10,875
-33.8%
0.05%
+138.1%
Q4 2017$959,000
+101.9%
16,424
+100.5%
0.02%
+90.9%
Q3 2017$475,0008,1910.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders